1. SIGN 153: British guideline on the management of asthma (revised edition 2016). Edinburgh: Scottish Intercollegiate Guidelines Network; 2016.
2. Relvar Ellipta inhalation powder. EU summary of product characteristics. London: European Medicines Agency; 2016.
3. Kaur M, Chivers JE, Giembycz MA, et al. Long-acting β2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol. 2008;73(1):203–14.
4. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527–39.
5. GlaxoSmithKline. RELVAR™ ELLIPTA™ gains approval in Japan for the treatment of asthma [media release]. 20 Sep 2013. http://www.gsk.com/ .